State Street Corp Contrafect Corp Transaction History

State Street Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.06 - $4.74 $7,789 - $615,332	-129,817 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$2.26 - $3.84 $73,592 - $125,041	32,563 Added 33.48%	129,817 $474,000
Q4 2021 Feb 14, 2022	BUY	$2.47 - $4.14 $54,340 - $91,080	22,000 Added 29.23%	97,254 $256,000
Q2 2021 Aug 16, 2021	SELL	$3.58 - $4.9 $905,274 - $1.24 Million	-252,870 Reduced 77.07%	75,254 $331,000
Q1 2021 May 17, 2021	BUY	$4.46 - $6.68 $38,989 - $58,396	8,742 Added 2.74%	328,124 $1.58 Million
Q4 2020 Feb 16, 2021	BUY	$5.05 - $6.4 $564,059 - $714,848	111,695 Added 53.78%	319,382 $1.61 Million
Q3 2020 Nov 10, 2020	BUY	$5.05 - $6.99 $132,633 - $183,585	26,264 Added 14.48%	207,687 $1.1 Million
Q2 2020 Aug 14, 2020	BUY	$4.69 - $7.81 $850,873 - $1.42 Million	181,423 New	181,423 $1.16 Million

49.2K

Ticker CFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,332,700
Market Cap $1.18M
Description
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.